UNSPSC 51111717: Trastuzumab

This classification denotes a monoclonal antibody with the molecular formula C6470H10012N1726O2013S42, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P188ANX8CK, more generally known as trastuzumab. European Medicines Agency schedules trastuzumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12612MIG. The term TRASTUZUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 2 1999, list 40.

UNSPSC 51111717 Trastuzumab is a Commodity code covering the procurement of this monoclonal antibody drug used primarily in the treatment of HER2-positive breast cancer and gastric cancer. State and local governments procure trastuzumab through health departments, Medicaid agencies, corrections systems, and public hospital networks to stock formularies, support inpatient and outpatient oncology programs, and meet treatment obligations for eligible patients. The drug is typically sourced through competitive bidding or established pharmaceutical supply contracts, often via group purchasing organizations or state health-system cooperative agreements that negotiate pricing and volume terms.

The source provided contains no recent state and local contract opportunities tagged to UNSPSC 51111717 Trastuzumab, making current market activity under this code not visible in the available data.